Startup GeneCentric Diagnostics pulled in $5 million in new Series A financing, according to reports from The Herald-Sun and Dow Jones VentureWire, among other media organizations. The money will help the North Carolina startup advance further development of gene-based diagnostic products designed to enable personalized treatments.
First there were digital clocks, then digital computers, and now digital medicines. Fierce 15 member Proteus Digital Health raised $120 million in its latest round of funding, the company announced June 2. The round of financing consists of "major institutional investors" from the U.S., Europe and Asia.
Roche's Ventana Medical Systems will work with Denmark's Genmab to come up with a companion diagnostic test to be paired with a targeted anticancer drug now in development.
GE Healthcare has developed a discount molecular imaging system for cancer detection, intended for physicians practicing personalized medicine in emerging markets--especially India, where the devicemaker got help designing the system.
Exosome Diagnostics announces this morning it has raised $27 million and will go to market in 2014 with its first fluid-based diagnostic test, a noninvasive urine sample designed to detect prostate cancer without a biopsy.
Fledgling California diagnostics startup Guardant Health has raised $10 million in a round led by Sequoia Capital. With money in hand, it is gearing up to sell a cancer test that depends on blood samples instead of biopsies, backed by next-generation sequencing.
The controversial 23andMe Personal Genome Test has demonstrated some interesting ancestry numbers, according to a blogger at The Unz Review.
Thorne Research is putting a recent acquisition in personalized medicine to work, partnering its WellnessFX division with blood diagnostics maker Itamar Medical to market a home test for sleep apnea.
One of the elements lacking in the personalized medicine discussion today is the perspective of leading clinicians, informaticists and academics working in the field. To remedy the gap, I've asked a series of leaders in the industry to offer up their views.
Biodesix grabbed $8.3 million in Series E financing to help boost sales and marketing efforts for its personalized medicine-focused lung cancer test.